Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. (Nasdaq: ARTL) on December 2, 2019, covering events occurring on December 2 and December 6, 2019. The Company is an emerging growth company incorporated in Nevada, focused on biotechnology, with principal executive offices in La Jolla, California.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes
The filing reports two material changes to the Board of Directors:
- Appointment of Director: On December 6, 2019, John W. Beck was appointed to the Board of Directors, effective immediately, with a term expiring at the 2020 annual meeting. He was also appointed Chair of the Audit Committee.
- Resignation of Director: On December 2, 2019, Georgia Erbez resigned from the Board effective immediately. The Company stated her resignation was not due to any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Compensation Details
Management provided specific details regarding the compensatory arrangements for the new director, John W. Beck:
- Equity Grants: Mr. Beck received an option to purchase 40,000 shares of common stock vesting monthly over four years for Board service, and a second option for 10,000 shares vesting monthly over two years for his role as Audit Committee Chair.
- Cash Retainer: An annual cash retainer is intended to commence on the earlier of the one-year anniversary of his start date or the date the Company raises at least $7,500,000 in equity financing.
- Retainer Amounts: Expected compensation is $15,000 to $20,000 for the first year and $20,000 to $30,000 for the second year and thereafter.
- Expenses: The Company will reimburse Mr. Beck for all reasonable expenses related to his services.
The filing confirms that the Board remains qualified as "independent" under Nasdaq listing standards following Ms. Erbez's resignation.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 50,000 total stock options granted to John W. Beck.
- Monitor the Company's capital raising activities to determine if the $7,500,000 equity financing threshold is met, which would trigger the cash retainer for Mr. Beck.
- Review the Company's 2018 Equity Incentive Plan to understand the full terms and conditions of the granted options.
- Confirm the composition of the Audit Committee to ensure continued compliance with Nasdaq independence standards.